IMPLICATIONS OF FLEROXACINS PHARMACOKINETIC PROFILE

被引:1
|
作者
NIGHTINGALE, CH
机构
[1] Hartford Hospital, Hartford, CT 06115
关键词
FLEROXACIN; PHARMACODYNAMICS; ELIMINATION; ABSORPTION; BODY DISTRIBUTION; DRUG INTERACTIONS;
D O I
10.1016/0924-8579(94)90016-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Fleroxacin, like all quinolones, is well absorbed, reaching peak concentrations within 2 h. Interactions with Ca2+ and Al3+ are minimal compared with other quinolones and possibly of little clinical importance. The drug is eliminated via filtration in the kidney. It is therefore sensitive to changes in renal function. Accumulation of drug in the body is minimal, and change from intravenous to oral dosing results in nearly identical serum concentrations. Aside from the modest effect of metals on its absorption, fleroxacin does not interact/compete with substances oxidized in the liver, such as theophylline, and drug interactions are minimal. Its long serum half-life (8-12 h) allows once-a-day dosing. This may be of particular pharmacodynamic advantage when treating infections caused by organisms with relatively high MIC's. This feature, along with its modest drug interactions, indicates that fleroxacin will probably be an important quinolone useful in a variety of clinical settings.
引用
收藏
页码:S7 / S13
页数:7
相关论文
共 50 条
  • [21] Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses
    Rogers, SL
    Friedhoff, LT
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 : 1 - 6
  • [22] Pharmacodynamic effects and pharmacokinetic profile of continuous infusion fentanyl in newborn piglets
    Rajan, V
    Beharry, KDA
    Williams, P
    Modanlou, HCD
    BIOLOGY OF THE NEONATE, 1998, 74 (01): : 39 - 47
  • [23] Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses
    Rogers, SL
    Cooper, NM
    Sukovaty, R
    Pederson, JE
    Lee, JN
    Friedhoff, LT
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 : 7 - 12
  • [24] Pharmacokinetic and pharmacodynamic changes in older adults and implications for palliative care
    Sera, Leah
    Uritsky, Tanya
    PROGRESS IN PALLIATIVE CARE, 2016, 24 (05) : 255 - 261
  • [25] Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis
    Weir, Scott
    Torkin, Risa
    Henney, Herbert R., III
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (12) : 1627 - 1636
  • [26] Clinical Effects and Pharmacokinetic Profile of Intramuscular Dexmedetomidine (10 μg/kg) in Cats
    Fernandes, Naftali S.
    Passos, Yanna D. B.
    Arcoverde, Kathryn N.
    Mouta, Andressa N.
    Paiva, Thaina C.
    Oliveira, Kalyne D. S.
    Araujo-Silva, Gabriel
    de Paula, Valeria Veras
    ANIMALS, 2024, 14 (15):
  • [27] Bioavailability and pharmacokinetic profile of levofloxacin following intravenous, intramuscular and oral administration in turkeys
    Aboubakr, M.
    Uney, K.
    Elmas, M.
    BRITISH POULTRY SCIENCE, 2014, 55 (01) : 115 - 119
  • [28] Pharmacokinetic variation
    Eusuf, Danielle, V
    Thomas, Elizabeth
    ANAESTHESIA AND INTENSIVE CARE MEDICINE, 2019, 20 (02) : 126 - 129
  • [29] Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management
    Li, Wei
    Zeng, Su
    Yu, Lu-Shan
    Zhou, Quan
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2013, 9 : 259 - 271
  • [30] Pharmacokinetic variation
    Eusuf, Danielle, V
    Thomas, Elizabeth
    ANAESTHESIA AND INTENSIVE CARE MEDICINE, 2022, 23 (01) : 50 - 53